Docetaxel [clinicaltrials_resource:86f76696ff0f69eded22351b61a4cd29]
Paclitaxel or Docetaxel in Treating Women With Advanced Breast Cancer [clinicaltrials:NCT00002662]clinicaltrials:NCT00002707Docetaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer [clinicaltrials:NCT00002775]Docetaxel in Treating Children With Recurrent Solid Tumors [clinicaltrials:NCT00002825]Docetaxel and Epirubicin With and Without G-CSF in Treating Women With Metastatic Breast Cancer [clinicaltrials:NCT00002866]Docetaxel in Treating Patients With Recurrent or Refractory Germ Cell Cancer [clinicaltrials:NCT00002903]Docetaxel Combined With Estramustine in Treating Women With Metastatic Breast Cancer [clinicaltrials:NCT00003066]Docetaxel in Treating Patients With Advanced Cancer of the Cervix [clinicaltrials:NCT00003445]Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [clinicaltrials:NCT00003560]Docetaxel in Treating Patients With Solid Tumors [clinicaltrials:NCT00003565]clinicaltrials:NCT00003587clinicaltrials:NCT00003762Docetaxel in Treating Patients With Stage IV Prostate Cancer [clinicaltrials:NCT00003781]clinicaltrials:NCT00003782Docetaxel Plus Carboplatin in Treating Patients With Advanced Cancer of the Esophagus [clinicaltrials:NCT00003864]clinicaltrials:NCT00003900clinicaltrials:NCT00003908clinicaltrials:NCT00003953Carboplatin Plus Paclitaxel or Docetaxel in Treating Patients With Ovarian Epithelial Cancer [clinicaltrials:NCT00003998]clinicaltrials:NCT00004001Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Cancer [clinicaltrials:NCT00004037]Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma [clinicaltrials:NCT00004066]Docetaxel in Treating Women With Ovarian Epithelial or Primary Peritoneal Cancer [clinicaltrials:NCT00004081]clinicaltrials:NCT00004139Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer [clinicaltrials:NCT00004223]clinicaltrials:NCT00004235Docetaxel and Oxaliplatin in Treating Patients With Metastatic or Recurrent Solid Tumor [clinicaltrials:NCT00004243]Docetaxel, Cisplatin, and Amifostine in Treating Patients With Advanced Non-small Cell Lung Cancer [clinicaltrials:NCT00004264]Docetaxel and Gemcitabine Compared With Docetaxel and Cisplatin in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer [clinicaltrials:NCT00004884]MS 209 Plus Docetaxel in Treating Patients With Advanced Solid Tumors [clinicaltrials:NCT00004886]clinicaltrials:NCT00004888Docetaxel and Irinotecan in Treating Patients With Advanced Solid Tumors [clinicaltrials:NCT00004923]Combination Chemotherapy and Surgery in Treating Patients With Locally Advanced Stomach Cancer [clinicaltrials:NCT00005060]Docetaxel in Treating Patients With Stage II or Stage III Prostate Cancer [clinicaltrials:NCT00005096]clinicaltrials:NCT00005800clinicaltrials:NCT00005810Trastuzumab and Docetaxel in Treating Patients Who Have Metastatic Prostate Cancer That Is Refractory to Hormone Therapy [clinicaltrials:NCT00005857]clinicaltrials:NCT00005908clinicaltrials:NCT00005963clinicaltrials:NCT00006010
intervention browse [clinicaltrials_vocabulary:intervention-browse]
Docetaxel [clinicaltrials_resource:86f76696ff0f69eded22351b61a4cd29]
Bio2RDF identifier
86f76696ff0f69eded22351b61a4cd29
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:86f76696ff0f69eded22351b61a4cd29
identifier
clinicaltrials_resource:86f76696ff0f69eded22351b61a4cd29
title
Docetaxel
@en
type
label
Docetaxel [clinicaltrials_resource:86f76696ff0f69eded22351b61a4cd29]
@en